Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Impression Healthcare has welcomed two established industry experts to its Medical Advisory Board.
  • Associate Professor Michael Stubbs and Dr David Cunnington will procure funding for and present research findings on the sleep apnoea and Temporomandibular clinical trials at Impression Healthcare over an initial two year period.
  • Impression conducts clinical trials to investigate the influence of medicinal cannabis products in treating sleep apnoea, traumatic brain injury, periodontitis, and Temporomandibular Joint Disorders.

Impression Healthcare has welcomed two established industry experts to its Medical Advisory Board.

Described as key opinion leaders in their fields, Associate Professor Michael Stubbs and Dr David Cunnington specialise in Temporomandibular Joint Disorders (TMD) and Sleep Apnoea respectively.

Overseen by Impression CEO and Cannvalate Chief Medical Officer, Dr Sud Agarwal, the Medical Advisory Board will assist with Impression’s four current clinical trials.

The newly appointed advisors join Dr Ron Jithoo and Dr Simon Hinckfuss, who will guide clinical programs based on the influence of cannabis products on concussions and periodontitis (commonly known as gum disease).

Michael and Dr David will procure funding for and present research findings on the sleep apnoea and Temporomandibular clinical trials at Impression Healthcare over an initial two year period.

Impression CEO Dr Sud Agarwal said the new advisors would be invaluable in shaping the company’s cannabinoid drug discovery programs.

“We’re delighted to have formally appointed another two experienced medical professionals, with solid academic research credentials, to the medical advisory board. Associate Professor Michael Stubbs and Dr David Cunnington are globally recognised Key Opinion Leaders (KOLs) in their clinical fields,” Dr Sud explained.

Michael is a Melbourne-based oral medicine specialist who treats facial and jaw pain associated with Temporomandibular Disorders. He works as an Associate Professor of oral medicine at Latrobe University and edits Australasian Dentist magazine.

Dr David, co-director of the Melbourne Sleep Disorders Centre, operates as a specialist sleep physician. An experienced sleep investigator and founder of online sleep resource SleepHub, he specialises in complex sleep issues. He is enthusiastic about increasing public education around sleep health and medication.

Based in Victoria, Impression Healthcare is an oral device and medical cannabis business. Currently, they conduct clinical trials to investigate the influence of medicinal cannabis products in treating sleep apnoea, traumatic brain injury, periodontitis, and Temporomandibular Joint Disorders.

The company has acquired a licence to import, export and distribute cannabis products Australia-wide, including their own line of CBD Incannex™ Oil. In an announcement last month, Impression reported their first batch of CBD Oil had been ordered by Linnea SA, a natural pharmaceuticals company.

Impression Healthcare also holds a binding distribution agreement with Cannvalate, the largest network of cannabis medicine prescribers in Australia. The company receives over 100 new patient enquiries every day.

IHL by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.